EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Artificial Intelligence in Drug Discovery: Integrative Advances From Data to Therapeutic Innovation

Mohammad Javad Mehran iD, Sara Mohammadzadeh iD, Mansoor Bolideei iD, Rambod Barzigar iD, Khawaja Husnain Haider, Nasir Jadgal, Yadollah Bahrami iD

Drug Development Research · 2026-04 · 87 (2)

DOI: 10.1002/ddr.70229 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 02.02.2026. Verfasst von Mohammad Javad Mehran und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. Hauptthemen laut MEDLINE: Drug Discovery, Artificial Intelligence. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 223 Literaturangaben. Gefördert von: Research and Technology of Kermanshah University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Integrating artificial intelligence (AI) into drug discovery revolutionizes pharmaceutical research by significantly accelerating the identification, optimization, and development of novel therapeutics. Conventional drug discovery methods, known for high costs, lengthy timelines, and low success rates, are increasingly being augmented by AI‐based technologies, including machine learning (ML), deep learning (DL), and reinforcement learning (RL). These advanced computational approaches enhance key processes, such as target identification, virtual screening, de novo drug design, toxicity prediction, and the optimization of pharmacokinetic and pharmacodynamic profiles, dramatically increasing overall efficiency. AI‐driven primary and secondary screening methods improve cell classification, compound prioritization, and drug‐target interaction predictions, substantially shortening the progression from preclinical phases to clinical trials. Additionally, AI enables retrosynthesis prediction and reaction yield modeling, optimizing chemical synthesis pathways and reducing the need for resource‐intensive experimental procedures. AI's integration into clinical trials has notably improved patient stratification, biomarker discovery, and adaptive trial designs, ultimately delivering more precise and economically feasible therapeutic interventions. Furthermore, AI supports polypharmacological approaches through multitarget drug discovery, drug repurposing (finding new uses for existing drugs), and adverse effect prediction, thereby advancing personalized medicine. Despite these transformative advantages, it's important to note that AI in drug discovery also has limitations, such as ensuring data quality, improving model interpretability, gaining regulatory acceptance, and addressing ethical concerns. This review comprehensively explores the impact of AI throughout the drug discovery pipeline, emphasizing its critical role in expediting the development of life‐saving medications and outlining future directions for continued pharmaceutical innovation driven by AI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DiscoveryArtificial IntelligenceHumansReinforcement Machine LearningDeep LearningMachine LearningAnimalsDrug Design

Stichwörter der Autor:innen

artificial intelligenceclinical trialsdeep learningdrug discoverymachine learningvirtual screening

Autor:innen und Institutionen

  • Department of Medical Biotechnology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Department of Biotechnology, JSS Research Foundation, SJCE Technical Campus, University of Mysore, Mysore, Karnataka, India.
  • NHC Key Laboratory of Respiratory Diseases, Department of Respiratory and Critical Care Medicine, The Center for Biomedical Research, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences and Technolo…
  • Department of Immunology, Chabahar Faculty of Medical Sciences, Chabahar, Iran.
  • Sulaiman AlRajhi Medical School, Al Bukayriyah, AlQaseem, Kingdom of Saudi Arabia.
  • Department of Nursing, Chabahar Faculty of Medical Sciences, Chabahar, Iran.

ORCID-Profile: Mohammad Javad Mehran, Sara Mohammadzadeh, Mansoor Bolideei, Rambod Barzigar, Yadollah Bahrami

Förderung

  • Research and Technology of Kermanshah University of Medical Sciences

Zitieren

APA

Mehran, M. J., Mohammadzadeh, S., Bolideei, M., Barzigar, R., Haider, K. H., Jadgal, N., & Bahrami, Y. (2026). Artificial Intelligence in Drug Discovery: Integrative Advances From Data to Therapeutic Innovation. Drug Development Research, 87(2). https://doi.org/10.1002/ddr.70229

Vancouver

Mehran MJ, Mohammadzadeh S, Bolideei M, Barzigar R, Haider KH, Jadgal N, et al. Artificial Intelligence in Drug Discovery: Integrative Advances From Data to Therapeutic Innovation. Drug Development Research. 2026;87(2). doi:10.1002/ddr.70229

BibTeX
@article{Mehran2026,
  author = {Mehran, Mohammad Javad and Mohammadzadeh, Sara and Bolideei, Mansoor and Barzigar, Rambod and Haider, Khawaja Husnain and Jadgal, Nasir and Bahrami, Yadollah},
  title = {Artificial Intelligence in Drug Discovery: Integrative Advances From Data to Therapeutic Innovation},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {2},
  doi = {10.1002/ddr.70229}
}
Kostenlos starten →